Prometheon Pharma is targeting an initial $15B/year domestic market with its needle-free insulin patch technology and its hair regrowth formula. Prometheon's business model generates profits even before the launch of its products, which eliminate needle injection for a variety of drugs. Their proprietary platform technology, developed at the University of Florida, allows large molecules, growth hormones, and potentially vaccines to be delivered in a 7-day patch as simple as a medicated band aid. Their topical hair regrowth gel delivers a naturally occurring compound long known to re-establish normal hair growth, but too large to deliver transdermally until now. This product is expected to dominate a fragmented market with low penetration in which leaders Rogaine and Propecia have just gone off patent.

Facebook | Twitter | LinkedIn